Mangalam Drugs & Organics Limited

BSE:532637 Stock Report

Market Cap: ₹1.7b

Mangalam Drugs & Organics Past Earnings Performance

Past criteria checks 3/6

Mangalam Drugs & Organics's earnings have been declining at an average annual rate of -26%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 4.4% per year. Mangalam Drugs & Organics's return on equity is 6.4%, and it has net margins of 2.6%.

Key information

-26.0%

Earnings growth rate

-26.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate4.4%
Return on equity6.4%
Net Margin2.6%
Next Earnings Update14 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Mangalam Drugs & Organics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:532637 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,552944110
30 Jun 243,568313980
31 Mar 243,674-914040
31 Dec 233,595-1703560
30 Sep 233,245-1713610
30 Jun 233,477-1133410
31 Mar 233,702133600
31 Dec 224,1091234240
30 Sep 224,4261594170
30 Jun 224,5051823880
31 Mar 224,5091973970
31 Dec 214,1851513470
30 Sep 214,0581753340
30 Jun 213,8132413080
31 Mar 213,8002803050
31 Dec 203,7743092940
30 Sep 203,5072612840
30 Jun 203,2101582780
31 Mar 202,824832700
31 Dec 192,423-282620
30 Sep 192,290-892620
30 Jun 192,336-802530
31 Mar 192,276-802660
31 Dec 182,467102590
30 Sep 182,7201142510
30 Jun 182,8331642400
31 Mar 182,7941992360
31 Dec 172,9042472280
30 Sep 172,9832482210
30 Jun 173,0442332010
31 Mar 173,0292231970
31 Dec 162,9062271840
30 Sep 162,9432031690
30 Jun 162,9191811430
31 Mar 162,9521601490
31 Dec 153,0011402158
30 Sep 152,8071102088
30 Jun 152,5161011150
31 Mar 152,207611130
31 Dec 141,783651628
30 Sep 141,556561628
30 Jun 141,425261030
31 Mar 141,227-301598

Quality Earnings: 532637 has high quality earnings.

Growing Profit Margin: 532637 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 532637 has become profitable over the past 5 years, growing earnings by -26% per year.

Accelerating Growth: 532637 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 532637 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).

Return on Equity

High ROE: 532637's Return on Equity (6.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 11:34
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mangalam Drugs & Organics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vijay MadunalaFirstCall Research